Mild decreases in white blood cell and platelet counts are present one year after radioactive iodine remnant ablation.
暂无分享,去创建一个
S. Larson | M. Fleisher | R. Tuttle | E. Molinaro | R. Leboeuf | A. Martorella | Brenda Shue | Andrew J. Martorella
[1] J. Tward,et al. The risk of second primary malignancies up to three decades after the treatment of differentiated thyroid cancer. , 2008, The Journal of clinical endocrinology and metabolism.
[2] R. Kloos,et al. Nasolacrimal drainage system obstruction from radioactive iodine therapy for thyroid carcinoma. , 2002, The Journal of clinical endocrinology and metabolism.
[3] N. Avril,et al. Radioimmunotherapy using 131I-rituximab in patients with advanced stage B-cell non-Hodgkin’s lymphoma: initial experience , 2005, European Journal of Nuclear Medicine and Molecular Imaging.
[4] P. Hall,et al. Second primary malignancies in thyroid cancer patients , 2003, British Journal of Cancer.
[5] S. Mandel,et al. Radioactive iodine and the salivary glands. , 2003, Thyroid : official journal of the American Thyroid Association.
[6] S. Larson,et al. Comparison of bone marrow dosimetry and toxic effect of high dose 131I-labeled monoclonal antibodies administered to man. , 1989, International journal of radiation applications and instrumentation. Part B, Nuclear medicine and biology.
[7] S. Larson,et al. A retrospective review of the effectiveness of recombinant human TSH as a preparation for radioiodine thyroid remnant ablation. , 2002, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[8] Markus Luster,et al. Iodine biokinetics and dosimetry in radioiodine therapy of thyroid cancer: procedures and results of a prospective international controlled study of ablation after rhTSH or hormone withdrawal. , 2006, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[9] M. Saghari,et al. Gonadal function in patients with differentiated thyroid cancer treated with (131)I. , 2004, Hellenic journal of nuclear medicine.
[10] F. Grünwald,et al. rhTSH stimulation before radioiodine therapy in thyroid cancer reduces the effective half-life of (131)I. , 2003, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[11] Gerard M Doherty,et al. Management guidelines for patients with thyroid nodules and differentiated thyroid cancer. , 2006, Thyroid : official journal of the American Thyroid Association.
[12] Haynie Tp,et al. Hematologic changes observed following I-131 therapy for thyroid carcinoma. , 1963 .
[13] M. Sonenberg,et al. The relation of radioiodine dosimetry to results and complications in the treatment of metastatic thyroid cancer. , 1962, The American journal of roentgenology, radium therapy, and nuclear medicine.
[14] M. Schott. Recombinant Human TSH–Assisted Radioactive Iodine Remnant Ablation Achieves Short-Term Clinical Recurrence Rates Similar to Those of Traditional Thyroid Hormone Withdrawal , 2008 .
[15] S. Purisch,et al. Preparation with Recombinant Human Thyroid-Stimulating Hormone for Thyroid Remnant Ablation with 131I Is Associated with Lowered Radiotoxicity , 2008, Journal of Nuclear Medicine.